Table 4 (A) Female Sexual Function Index (FSFI) and (B) Female Sexual Distress Scale (FSDS) intragroup and intergroup comparison of women with endometriosis-associated pain symptoms at baseline and at 3, 6 and 12 months of 24/4 regimen 17β-estradiol (1.5 mg) and Nomegestrol Acetate (2.5 mg) (E2/NOMAC) combined oral contraceptive, or of Dienogest (DNG) 2 mg daily
FSFI score | Baseline | 3rd month follow-up | 6th month follow-up | 12th month follow-up | p |
|---|---|---|---|---|---|
A | |||||
E2/NOMAC Group | 20.8 ± 1.9 | 27.5 ± 1.6 | 28.6 ± 2.5 | 30.2 ± 2.8 | < 0.001 |
DNG Group | 21.1 ± 1.2 | 27.8 ± 1.3 | 29.7 ± 2.9 | 31.3 ± 2.7 | < 0.001 |
p | 0.18 95% CI − 0.7 to 0.1 | 0.15 95% CI − 0.7 to 0.1 | 0.005 95% CI − 1.8 to − 0.3 | 0.006 95% CI − 1.8 to − 0.3 |
FSDS score | Baseline | 3rd month follow-up | 6th month follow-up | 12th-month follow-up | p |
|---|---|---|---|---|---|
B | |||||
E2/NOMAC Group | 18.5 ± 1.5 | 13.6 ± 1.7 | 10.2 ± 1.8 | 10 ± 1.4 | < 0.001 |
DNG Group | 18.4 ± 1.3 | 11.3 ± 1.4 | 10.1 ± 1.6 | 9.8 ± 1.5 | < 0.001 |
p | 0.6 95% CI − 0.3 to 0.5 | < 0.001 95% CI 1.8 to 2 | 0.68 95% CI − 0.4 to 0.6 | 0.33 95% CI − 0.2 to 0–6 |